Mirador valuation, funding and investors
Mirador works in precision medicine development, based in San Diego, United States. Founded in 2024, it has about 97 employees.
- Last round
- Series B · $250M · Sep 2025
- Valuation at last round
- $1.79B · implied
- Headcount
- 97 · up
- Grade
- C
- Founded
- 2024
Mirador valuation today
VCMC values Mirador at $2.8B today, with a range of $1.2B to $4.3B and a grade of C. The valuation starts from its last funding round, a Series B round in Sep 2025.
Valuation by date (36 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2024 | $22.7M | $8.26M – $62.3M | $23.7M (+5%) | before first round | – | unknown | D | 0% |
| 1 Feb 2024 | $22.8M | $8.32M – $62.8M | $23.7M (+4%) | before first round | – | unknown | D | 0% |
| 1 Mar 2024 | $23.0M | $8.38M – $63.2M | $23.7M (+3%) | before first round | – | unknown | D | 0% |
| 22 Mar 2024 | $2.2B | $1.5B – $6.1B | $4.0B (+80%) | after a round | – | unknown | C | 0% |
| 1 Apr 2024 | $2.3B | $1.5B – $6.1B | $4.0B (+77%) | after a round | – | unknown | C | 0% |
| 1 May 2024 | $2.4B | $1.5B – $6.1B | $4.0B (+69%) | after a round | – | unknown | C | 0% |
| 1 Jun 2024 | $2.5B | $1.5B – $6.1B | $4.0B (+60%) | after a round | – | unknown | C | 0% |
| 1 Jul 2024 | $2.6B | $1.5B – $6.1B | $4.0B (+53%) | after a round | – | unknown | C | 0% |
| 1 Aug 2024 | $2.8B | $1.5B – $6.1B | $4.0B (+45%) | after a round | 24 | unknown | C | 0% |
| 1 Sep 2024 | $2.9B | $1.5B – $6.1B | $4.0B (+38%) | after a round | 24 | unknown | C | 0% |
| 1 Oct 2024 | $3.0B | $1.5B – $6.1B | $4.0B (+32%) | after a round | 24 | unknown | C | 0% |
| 1 Nov 2024 | $3.5B | $1.7B – $6.9B | $4.5B (+32%) | after a round | 43 | growing | C | 0% |
| 1 Dec 2024 | $3.7B | $1.7B – $6.9B | $4.5B (+24%) | after a round | 43 | growing | C | 0% |
| 1 Jan 2025 | $3.9B | $1.7B – $6.9B | $4.5B (+17%) | after a round | 43 | growing | C | 0% |
| 1 Feb 2025 | $4.1B | $1.7B – $6.9B | $4.5B (+10%) | after a round | 43 | growing | C | 0% |
| 1 Mar 2025 | $4.4B | $1.7B – $6.9B | $4.5B (+4%) | after a round | 43 | growing | C | 0% |
| 1 Apr 2025 | $4.5B | $1.7B – $6.9B | $4.5B (0%) | after a round | 43 | growing | C | 0% |
| 1 May 2025 | $4.5B | $1.7B – $6.9B | $4.5B (0%) | after a round | 43 | growing | C | 0% |
| 1 Jun 2025 | $4.5B | $1.7B – $6.9B | $4.5B (0%) | after a round | 43 | growing | C | 0% |
| 1 Jul 2025 | $4.5B | $1.7B – $6.9B | $4.5B (0%) | after a round | 43 | growing | C | 0% |
| 1 Aug 2025 | $5.2B | $2.0B – $7.9B | $5.2B (0%) | after a round | 77 | growing | C | 0% |
| 1 Sep 2025 | $5.2B | $2.1B – $7.9B | $5.2B (0%) | after a round | 80 | growing | C | 0% |
| 1 Oct 2025 | $1.8B | $1.2B – $4.1B | $2.7B (+50%) | after a round | 80 | growing | C | 0% |
| 1 Nov 2025 | $1.9B | $1.2B – $4.2B | $2.7B (+47%) | after a round | 87 | growing | C | 0% |
| 1 Dec 2025 | $1.9B | $1.2B – $4.2B | $2.7B (+43%) | after a round | 90 | growing | C | 0% |
| 1 Jan 2026 | $2.0B | $1.2B – $4.2B | $2.7B (+38%) | after a round | 90 | growing | C | 0% |
| 1 Feb 2026 | $2.1B | $1.2B – $4.2B | $2.7B (+33%) | after a round | 90 | growing | C | 0% |
| 1 Mar 2026 | $2.1B | $1.2B – $4.2B | $2.8B (+29%) | after a round | 94 | growing | C | 0% |
| 1 Apr 2026 | $2.2B | $1.2B – $4.2B | $2.8B (+25%) | after a round | 94 | growing | C | 0% |
| 1 May 2026 | $2.3B | $1.2B – $4.3B | $2.8B (+21%) | after a round | 97 | growing | C | 0% |
| 1 Jun 2026 | $2.4B | $1.2B – $4.3B | $2.8B (+16%) | after a round | 97 | up | C | 0% |
| 1 Jul 2026 | $2.5B | $1.2B – $4.3B | $2.8B (+12%) | after a round | 97 | up | C | 0% |
| 1 Aug 2026 | $2.6B | $1.2B – $4.3B | $2.8B (+8%) | after a round | 98 | up | C | 0% |
| 1 Sep 2026 | $2.7B | $1.2B – $4.3B | $2.8B (+4%) | after a round | 98 | up | C | 0% |
| 1 Oct 2026 | $2.8B | $1.2B – $4.3B | $2.8B (0%) | after a round | 97 | up | C | 0% |
| 24 Oct 2026 | $2.8B | $1.2B – $4.3B | $2.8B (0%) | after a round | 97 | up | C | 0% |
Key facts about Mirador
- Founded
- 2024
- Headquarters
- San Diego, United States
- Employees
- about 97 +21% in a year
- Total raised
- $650M
- Funding rounds
- 2
- Last round
- Series B Sep 2025
Mirador was founded in 2024 by Mark C. McKenna.
Mirador funding history
Mirador has 2 funding rounds on record, from Mar 2024 to Sep 2025, $650M in total. None disclosed a valuation.
Series B 30 Sep 2025
Led by T. Rowe Price Investment Management, Inc., Fidelity Management & Research Company; with Adage Capital Partners L.P., ARCH Venture Partners, OrbiMed, Fairmount, Point72, Farallon, Boxer Capital, TCG Crossover, Invus, Logos Capital, Moore Strategic Ventures, Blue Owl Capital, Woodline Partners, Venrock.
Sources: miradortx.com, finsmes.com, opusrecruiter.com and 1 more
$250M
Series A 21 Mar 2024
Led by ARCH Venture Partners; with OrbiMed, Sanofi, Fairmount Partners, Fidelity, Point72 Ventures, Farallon, Boxer Capital, TCG Crossover, Invus, Logos Capital, Moore Strategic Ventures, Blue Owl Capital, Woodline Partners, Venrock, RTW Investments, Alexandria Venture Investments.
Sources: alleywatch.com, lw.com, miradortx.com and 1 more
$400M
Mirador investors
23 investors have backed Mirador; ARCH Venture Partners, Fidelity Management & Research Company and T. Rowe Price Investment Management, Inc. led at least one round.
- ARCH Venture Partners lead, 2 rounds
- Fidelity Management & Research Company lead
- T. Rowe Price Investment Management, Inc. lead
- Blue Owl Capital 2 rounds
- Invus 2 rounds
- Moore Strategic Ventures 2 rounds
- Venrock 2 rounds
- Adage Capital Partners L.P.
- Alexandria Venture Investments
- Fairmount
- Fidelity
- Logos Capital
- Point72 Ventures
- Sanofi
What Mirador does
Mirador works in biotechnology, with 11 recorded offerings and customers in biotechnology and healthcare.
Mirador Therapeutics, Inc. is an American biotechnology company engaged in precision medicine for immune-mediated inflammatory and fibrotic diseases. The company develops precision therapies using multi-modal data and analytics, with a focus on immunology and inflammation. Mirador also operates a precision development engine that integrates human genetics and data science to support the development of new treatments.
Description from Veridion's company data.
Products and services
- Precision Medicine Development
- Immune-Mediated Disease Therapeutics Development
- Fibrotic Disease Therapeutics Development
- Genetic Data Analysis and Integration
- Immunology Data Science Services
- Multi-Modal Data Integration Services
- Precision Medicine Platform Development
- Drug Candidate Acceleration Services
- Clinical Trial Advancement Services
- Translational Immunology Research Services
- Precision Therapy Commercialization
Markets
- Biotechnology
- Healthcare
Technology
- Precision Medicine Algorithms
- Multi-Modal Data Analytics
- Advanced Analytics for Precision Medicine
Business model
- Business-to-Business
- Manufacturing
- Enterprise
Industry codes (NAICS)
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match
Questions about Mirador
What is Mirador worth?
Valuation $2.8B (range $1.2B to $4.3B), as of 24 Oct 2026.
Has Mirador raised money?
Mirador has 2 funding rounds on record, from Mar 2024 to Sep 2025, $650M in total. None disclosed a valuation.
Who has invested in Mirador?
ARCH Venture Partners, Fidelity Management & Research Company, T. Rowe Price Investment Management, Inc., Blue Owl Capital, Boxer Capital and Farallon, and 17 more. Lead investors include ARCH Venture Partners, Fidelity Management & Research Company and T. Rowe Price Investment Management, Inc..
How many people work at Mirador?
About 97, up 21% over the last year. Headcount grew from 24 in Aug 2024 to 97 in Sep 2026.
What does Mirador do?
Mirador works in biotechnology, with 11 recorded offerings and customers in biotechnology and healthcare. Its main offerings are precision medicine development, immune-mediated disease therapeutics development and fibrotic disease therapeutics development.
When was Mirador founded, and where is it based?
Mirador was founded in 2024 and is based in San Diego, United States. It has about 97 employees, up 21% over the last year.